Trial · NCT01190735
Caffeine for Motor Manifestations of Parkinson's Disease
NCT01190735, Phase 2, Completed, Ron Postuma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Caffeine for Motor Manifestations of Parkinson's Disease. Trials, record NCT01190735. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01190735
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Caffeine for Motor Manifestations of Parkinson's Disease
- NCT number
- NCT01190735
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 28 participants, actual
- Lead sponsor
- Ron Postuma
- Conditions
- Parkinson's Disease
- Interventions
- Caffeine alkaloid
- First posted
- 2010-08-30
- Last updated
- 2015-04-16
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tolerability | 6 weeks | Patients will be given a structured questionnaire targeting common side effects of caffeine, as well as a series of open-ended questions for other side effects. Vital signs will be measured. Questionnaire symptoms will be selected, where available, from the common terminology criteria for adverse events, version 3.0, developed by the National Cancer Institute. A severity of 2 or greater on the 5-point scale will delineate a dose-limiting effect. Evaluations will occur in person after 2 weeks, 4 weeks, 6 weeks (at study termination) and via telephone follow-up at the end of weeks 1,3 and 5. |
| Secondary | Epworth Sleepiness Scale (ESS) | 6 weeks | Will systematically track changes in ESS. |
| Secondary | Unified Parkinson Disease Rating Scale(UPDRS): Part II | 6 weeks | Systematically performing part II of the UPDRS, motor examination. |
| Secondary | Timed Up and Go (TUG) | 6 weeks | This is a measure of gait and transfer speed. |
| Secondary | Clinical Global Impression of Change | 6 weeks | |
| Secondary | Pittsburgh Sleep Quality Index | 6 weeks | |
| Secondary | Fatigue Severity Scale | 6 weeks | |
| Secondary | The Parkinson's Disease Questionnaire - PDQ-39 | 6 weeks | This self-completion questionnaire addresses aspects of functioning and well-being in those affected by Parkinson's Disease (PD). Considered to be the industry 'gold standard' in the assessment of quality of life in PD patients. The 39-point PDQ provides scores on 8 scales: mobility, activities of daily living, emotions, stigma, social support, cognition, communications and bodily discomfort. |
| Secondary | Beck Depression Inventory | 6 weeks | Self-administered questionnaire. |
| Secondary | Beck Anxiety Inventory | 6 weeks | Self-administered questionnaire. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01190735
GET https://conductscience.org/api/trials/v1/NCT01190735/registered